Administration of antisera to vasoactive intestinal polypeptide and peptide histidine isoleucine attenuates ether-induced prolactin secretion in rats.

Kaji H, Chihara K, Kita T, Kashio Y, Okimura Y, Fujita T

Neuroendocrinology1 Dec 1985Cited by 26 (Europe PMC)

PMID3841194DOI10.1159/000124231PepBankPUB-03841194

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome
In male rats, ether exposure raised plasma prolactin in all groups tested, including controls.
In plain wordsIn rats, ether stress raised blood prolactin in every group, including the control group.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePlasma prolactin rise after ether exposure in all groups
Study
ratn: not reported in source
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
Ether exposure caused a prompt and significant increase in plasma PRL in all of the animal groups tested.
1 context sentence(design, population, supporting numbers)
Summary · context
was examined in male rats bearing an indwelling atrial catheter.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0384119401
02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome
In male rats, pretreatment with anti-VIP or anti-PHI serum did not change basal plasma prolactin compared with normal rabbit serum.
In plain wordsIn rats, antisera against VIP or PHI did not change blood prolactin at rest, compared with normal serum.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeBasal plasma prolactin after antisera
Study
ratn: not reported in source
Comparator
Normal rabbit serum
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
Pretreatment with either antisera did not affect basal plasma PRL levels
1 context sentence(design, population, supporting numbers)
Summary · context
was examined in male rats bearing an indwelling atrial catheter.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0384119402
03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome
In male rats, anti-VIP serum, which neutralizes natural VIP, lowered the plasma prolactin rise after ether exposure compared with normal rabbit serum.
In plain wordsIn rats, an antiserum that blocks the body's own VIP reduced the prolactin rise after ether stress, compared with normal serum.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseEther-induced prolactin rise after anti-VIP serum
Study
ratn: not reported in source
Comparator
Normal rabbit serum
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
plasma PRL rises after ether exposure were significantly lower in rats pretreated with AVS, APS or AVS plus APS than those with NRS
1 context sentence(design, population, supporting numbers)
Summary · context
was examined in male rats bearing an indwelling atrial catheter.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0384119403
04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome
In male rats, anti-VIP serum plus anti-PHI serum lowered the plasma prolactin rise after ether exposure compared with normal rabbit serum.
In plain wordsIn rats, antisera that block the body's own VIP and PHI together reduced the prolactin rise after ether stress, compared with normal serum.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseEther-induced prolactin rise after anti-VIP plus anti-PHI serum
Study
ratn: not reported in source
Comparator
Normal rabbit serum
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
plasma PRL rises after ether exposure were significantly lower in rats pretreated with AVS, APS or AVS plus APS than those with NRS
1 context sentence(design, population, supporting numbers)
Summary · context
was examined in male rats bearing an indwelling atrial catheter.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0384119404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.